US · NTRA · MEDICAL - DIAGNOSTICS & RESEARCH
Natera, Inc. (NTRA) intrinsic value and stock valuation
$273.40as of 2026-11-21 · Mkt cap 39.33B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Natera, Inc. DCF and intrinsic value
InvestorsCraft values NTRA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from NTRA’s statements →
Natera, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Teva Pharmaceutical Industries Limited (TEVA) $39.23
- IQVIA Holdings Inc. (IQV) $245.82
- DexCom, Inc. (DXCM) $79.32
- Illumina, Inc. (ILMN) $192.82
- Mettler-Toledo International Inc. (MTD) $1,666.88
- Waters Corporation (WAT) $440.45
- Quest Diagnostics Incorporated (DGX) $258.28
- Koninklijke Philips N.V. (PHG) $28.61
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.31B | $1.7B | $1.08B | $820.2M | $625.5M |
| Operating income | -$-309.91M | -$-222.29M | -$-446.25M | -$-541.04M | -$-468.17M |
| Net income | -$-208.16M | -$-190.43M | -$-434.8M | -$-547.8M | -$-471.72M |
| EPSd | -$-1.52M | -$-1.53M | -$-3.78M | -$-5.57M | -$-5.21M |
| Operating cash flow | $215.3M | $135.7M | -$-246.96M | -$-431.5M | -$-335.24M |
| Capital expenditure | -$-106.19M | -$-66.42M | -$-39.2M | -$-47.7M | -$-41.03M |
| Free cash flow | $109.1M | $69.2M | -$-286.15M | -$-479.2M | -$-376.27M |
| Total assets | $2.51B | $1.66B | $1.44B | $1.39B | $1.24B |
| Total debt | $214.4M | $187.1M | $442M | $446.2M | $397.2M |
| Net debt | -$-861.76M | -$-758.47M | -$-200.1M | -$-19.87M | $312.9M |
| Total equity | $1.71B | $1.2B | $765.3M | $705.7M | $653.3M |
| Cash and short-term investments | $1.08B | $968.3M | $879M | $898.4M | $914.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.31B | $1.7B | $1.08B | $820.2M | $625.5M |
| Cost of revenue | $810.6M | $673.8M | $589.8M | $456.3M | $318.4M |
| Gross profit | $1.5B | $1.02B | $492.7M | $364M | $307.1M |
| Research and development expenses | $624.1M | $404.1M | $320.7M | $316.4M | $264.2M |
| Selling, general and administrative expenses | $1.18B | $841.3M | $618.3M | $588.6M | $511M |
| Other expenses | $4.03M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.81B | $1.25B | $939M | $905M | $775.2M |
| Cost and expenses | $2.62B | $1.92B | $1.53B | $1.36B | $1.09B |
| Interest income | $45.9M | $43.3M | $24.4M | $3.54M | $5.38M |
| Interest expense | $4.07M | $10.7M | $12.6M | $9.32M | $8.3M |
| Depreciation and amortization | $43.5M | $31M | $38.6M | $30.5M | $11.3M |
| Ebitda | -$-220.54M | -$-148.08M | -$-383.28M | -$-507.03M | -$-451.54M |
| Operating income | -$-309.91M | -$-222.29M | -$-446.25M | -$-541.04M | -$-468.17M |
| Total other income/expenses, net | $41.8M | $32.6M | $11.7M | -$-5.78M | -$-2.92M |
| Income before tax | -$-268.09M | -$-189.73M | -$-434.53M | -$-546.82M | -$-471.1M |
| Income tax expense | -$-59.93M | $690K | $270K | $980K | $620K |
| Net income | -$-208.16M | -$-190.43M | -$-434.8M | -$-547.8M | -$-471.72M |
| Weighted average shares outstanding | $136.7M | $124.7M | $115M | $98.4M | $90.6M |
| Weighted average diluted shares outstanding | $136.7M | $124.7M | $115M | $98.4M | $90.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.08B | $968.3M | $879M | $898.4M | $914.3M |
| Net receivables | $296.5M | $314.2M | $278.3M | $244.4M | $122.1M |
| Inventory | $68.4M | $44.7M | $40.8M | $35.4M | $26.9M |
| Total current assets | $1.5B | $1.38B | $1.26B | $1.21B | $1.09B |
| Property, plant and equipment, net | $349.7M | $248.2M | $167.8M | $164.3M | $124.5M |
| Goodwill and intangible assets | $514.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.01B | $284.9M | $183.2M | $182.7M | $143.4M |
| Total assets | $2.51B | $1.66B | $1.44B | $1.39B | $1.24B |
| Accounts payable | $33.2M | $34.9M | $15M | $31.2M | $27.2M |
| Short-term debt | $95.9M | $90.5M | $92M | $88M | $55.8M |
| Deferred revenue | $24.9M | $19.8M | $16.6M | $10.8M | $7.4M |
| Total current liabilities | $441.2M | $344.1M | $307.3M | $310.5M | $219M |
| Long-term debt | $118.5M | $96.6M | $350M | $358.2M | $341.4M |
| Deferred revenue, non-current | $17.1M | $16.8M | $19.1M | $20M | $21.3M |
| Total non-current liabilities | $354.4M | $121.3M | $369.1M | $378.2M | $364.2M |
| Capital lease obligations | $134.1M | $106.8M | $78.7M | $84.2M | $66.8M |
| Total liabilities | $795.6M | $465.3M | $676.4M | $688.7M | $583.2M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-2.78B | -$-2.57B | -$-2.38B | -$-1.94B | -$-1.39B |
| Accumulated other comprehensive income (loss) | -$-260K | -$-340K | -$-3.08M | -$-16.36M | -$-2.29M |
| Total equity | $1.71B | $1.2B | $765.3M | $705.7M | $653.3M |
| Total investments | $0.00 | $22.7M | $236.9M | $432.3M | $829.9M |
| Total debt | $214.4M | $187.1M | $442M | $446.2M | $397.2M |
| Net debt | -$-861.76M | -$-758.47M | -$-200.1M | -$-19.87M | $312.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-208.16M | -$-190.43M | -$-434.8M | -$-547.8M | -$-471.72M |
| Depreciation and amortization | $43.5M | $31M | $24.1M | $16.7M | $11.3M |
| Stock-based compensation | $354.4M | $274.4M | $191.8M | $152.4M | $115.2M |
| Change in working capital | $10M | $2.14M | -$-47.95M | -$-83.15M | -$-45.6M |
| Accounts receivable | $20.8M | -$-35.88M | -$-33.9M | -$-122.31M | -$-43.51M |
| Inventory | -$-20.87M | -$-3.98M | -$-5.35M | -$-8.5M | -$-6.88M |
| Accounts payable | $750K | $13.2M | -$-15.46M | $5.46M | $19.2M |
| Net cash provided by operating activities | $215.3M | $135.7M | -$-246.96M | -$-431.5M | -$-335.24M |
| Investments in property, plant and equipment | -$-139.19M | -$-66.42M | -$-39.2M | -$-47.7M | -$-41.03M |
| Acquisitions, net | -$-16.02M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-132.21M | $137.6M | $168.5M | $330.3M | -$-205.19M |
| Common stock issued | $47.5M | $30.3M | $254.5M | $452.6M | $576.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $47.5M | $30.2M | $254.5M | $482.6M | $576.2M |
| Net change in cash | $130.6M | $303.5M | $176M | $381.5M | $35.8M |
| Cash at end of period | $1.08B | $945.6M | $642.1M | $466.1M | $84.6M |
| Operating cash flow | $215.3M | $135.7M | -$-246.96M | -$-431.5M | -$-335.24M |
| Capital expenditure | -$-106.19M | -$-66.42M | -$-39.2M | -$-47.7M | -$-41.03M |
| Free cash flow | $109.1M | $69.2M | -$-286.15M | -$-479.2M | -$-376.27M |
Line items
Line items
Line items
About Natera, Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
- CEO
- Steven Leonard Chapman
- Employees
- 6.14K
- Beta
- 1.50
Explore
Frequently asked questions
What is the intrinsic value of Natera, Inc. (NTRA)?
Natera, Inc. (NTRA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NTRA undervalued?
NTRA trades at a price of $273.40 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.